We focus on the segments of pharmaceutical manufacturing where barriers to entry are highest and operational expertise creates the most durable competitive advantage.
Sterile injectables for hospital formularies and specialty indications, targeting FDA and EMA-regulated markets where quality systems and supply reliability command premium positioning
Vaccine and biologic manufacturing platforms with established WHO prequalification, technology transfer capability, and fill-finish infrastructure.
Contract development and manufacturing organizations with regulated capabilities, strategic customer relationships, and untapped capacity optimization potential.
We pursue control positions in businesses where our operational involvement directly accelerates value creation — not minority stakes where we are passengers.
Enabling us to set strategy, drive operational change, and make transformational decisions without friction
Expertise in acquiring businesses separated from larger pharmaceutical groups
Converting complexity into enterprise value
Deep operational assessments and lean manufacturing
implementation to structurally reduce cost of goods and
improve margin.
Investment in robust QMS infrastructure — remediation, facility upgrades, and inspection readiness.
Restructuring supply chains for resilience and cost efficiency — dual sourcing critical APIs and rationalising vendor bases.
Culling low-margin SKUs, prioritising high-value regulated market filings, and building development pipelines aligned to opportunity.
Developing market access strategies, customer relationships, and distribution partnerships for U.S. and European markets.